Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark.
J Pharm Pharmacol. 2011 Jun;63(6):817-24. doi: 10.1111/j.2042-7158.2011.01286.x. Epub 2011 May 3.
The aim of this study was to examine the effects of bile on the oral absorption of the poorly water-soluble compound, halofantrine, when administered to rats in vehicles consisting of the co-solvent polyethylene glycol 400 (PEG 400) alone or in mixtures with the surfactant polysorbate 80 (PS 80) (95:5; 85:15; 75:25 PEG 400:PS 80).
Halofantrine (17.5 mg/kg) was administered to bile duct cannulated (BDC) and sham-operated rats in a fixed vehicle volume of 5 ml/kg.
The bioavailability of halofantrine was significantly lower in BDC rats when dosed with 0-5% PS 80 in PEG 400 compared with BDC rats dosed with >15% PS 80. Increasing the concentration of PS 80 to 15-100% eliminated this difference. A possible explanation for the lower bioavailability of halofantrine in BDC rats when dosed in pure PEG 400 could be the dilution of the vehicle by intestinal fluids, decreased transit time and precipitation in the gastrointestinal tract upon dilution of PEG 400.
The addition of PS 80 to the formulation increased its solubilising power upon dilution and may have inhibited precipitation and substituted the absence of bile above a certain level. Adjusting the level of surfactant in drug formulations could therefore be used to minimise variability in the bioavailability from co-solvent systems based upon differences in bile concentration between individuals.
本研究旨在考察胆汁对水溶性差的化合物卤泛群在大鼠体内经单独使用混合溶剂聚乙二醇 400(PEG 400)或与表面活性剂聚山梨酯 80(PS 80)(95:5;85:15;75:25 PEG 400:PS 80)混合载体给药时的口服吸收的影响。
将卤泛群(17.5mg/kg)以 5ml/kg 的固定载体体积给予胆管插管(BDC)和假手术大鼠。
与 BDC 大鼠给予 >15% PS 80 相比,BDC 大鼠给予 0-5% PS 80 与 PEG 400 混合时,卤泛群的生物利用度显著降低。将 PS 80 的浓度增加到 15-100%可消除这种差异。BDC 大鼠在纯 PEG 400 中给药时,卤泛群生物利用度较低的可能原因是肠道液对载体的稀释、通过时间缩短以及 PEG 400 稀释时在胃肠道中沉淀。
表面活性剂 PS 80 的加入增加了制剂在稀释时的增溶能力,并可能抑制了沉淀,在一定水平以上替代了胆汁的缺失。因此,调整药物制剂中表面活性剂的水平可用于最小化基于个体胆汁浓度差异的混合溶剂系统的生物利用度的变异性。